Ann: Validation for NNZ-2591 neurodevelopmental disorder pipeline, page-23

Good announcement but not a half bagger. Good thing to take out of it is extrapolate this reaction out X times when we finally get rid of Lanstead and ROW comes through. Keep picking up loose stock where you can and just put them in the bottom drawer until d-day. Even more positive is that today's announcements may have increased ex-ACADIA co's to have a few more reasons to not just have a look at Trof, but maybe a company-wide viewing. My opinion, but this still looks like the best risk/reward biotech on the market at the moment. As we've just seen, she's a coiled spring and people with money clearly have eyes on it based on the $1.5m traded today already.